Contents:

The Pain Market Outlook to 2011 Executive Summary Patient potential Global market analysis Analysis of potential future blockbusters Leading players in the global pain market Chapter 1 Patient potential Summary Introduction Neuropathic pain Lower back pain Background Diagnosis, treatment and management Epidemiology Neuralgia/fibromyalgia Background Diagnosis, treatment and management Epidemiology Diabetic neuropathic pain Background Diagnosis, treatment and management Epidemiology Pain associated with multiple sclerosis Background Diagnosis, treatment and management Epidemiology Nociceptive pain Arthritic pain Background Diagnosis, treatment and management Epidemiology Post-operative pain Background Diagnosis, treatment and management Epidemiology Cancer-related pain Background Diagnosis, treatment and management Epidemiology HIV related pain Background Diagnosis, treatment and management Epidemiology Chapter 2 Global market analysis Summary Introduction Pain market analysis Leading brands in the global pain market Opioid market analysis Leading brands in the global opioid market Long-acting opioid market analysis Key brands analysis Short-acting opioid market analysis Key brands analysis Class sales forecast to 2011 Non-opioid market analysis Leading brands in the non-opioid market Key brands analysis Class sales forecast to 2011 Non-steroidal anti-inflammatory drugs Leading brands in the NSAID market Key brands analysis Class sales forecast to 2011 Cox-II inhibitor market analysis Leading brands in the COX-II inhibitor market Key brands analysis Class sales forecast to 2011 Anti-convulsants market analysis Leading brands in the anti-convulsant market First-generation anti-convulsants Key brands analysis Second-generation anti-convulsants Key brands analysis Class sales forecast to 2011 Global pain market forecasts to 2011 Chapter 3 Analysis of potential future blockbusters Summary Introduction Major approaches to R&D Leading drugs in development Drug profiles Phase II pipeline drugs NW-1029 (ralfinamide) Phase III pipeline drugs Tapentadol (CG5503/R33133) Bicifadine Transacin (NGX-4010) Neurodex (dectromorphan/quinidine) Chronogesic (sufentanil) Lacosamide M6G (morphine-6-glucuronide) Licofelone (ML3000) Recently marketed drugs Lyrica (pregabalin) Prialt (ziconotide) IONSYS (fentanyl iontophoretic transdermal system) DepoDur (morphine) Prexige (lumiracoxib) Forecast sales potential Chapter 4 Leading players in the global pain market Summary Introduction Global market shares Pfizer Marketed products R&D compounds Pain portfolio forecasts to 2011 Johnson & Johnson Marketed products R&D compounds Pain portfolio forecasts to 2011 Novartis Marketed products R&D compounds Pain portfolio forecasts to 2011 GlaxoSmithKline Marketed products R&D compounds Pain portfolio forecasts to 2011 Mundipharma Int. Marketed products R&D compounds Pain portfolio forecasts to 2011 Abbott Marketed products R&D compounds Pain portfolio forecasts to 2011 Boehringer Ingelheim Marketed products R&D compounds Pain portfolio forecasts to 2011 Sanofi-Aventis Marketed products R&D compounds Pain portfolio forecasts to 2011 Chapter 5 Appendix IMS sales data Index Glossary List of Figures Figure 1.1: Types of diabetic neuropathy Figure 1.2: Types of pain in multiple sclerosis Figure 1.3: Types of nociceptive cancer-related pain Figure 1.4: Sources of nociceptive HIV-related pain Figure 2.5: Competitive dynamics of the global pain market by drug class, 2005 Figure 2.6: Competitive dynamics of the leading products in the global pain market, 2005 Figure 2.7: Competitive dynamics of the leading opioid products in the global pain market, 2005 Figure 2.8: Competitive dynamics of the leading non-opioid products in the global pain market, 2005 Figure 2.9: Competitive dynamics of the leading NSAID products in the global pain market, 2005 Figure 2.10: Competitive dynamics of the leading COX-II inhibitor brands in the global pain market, 2005 Figure 2.11: Competitive dynamics of the leading anti-convulsant products in the global pain market, 2005 Figure 3.12: Leading recently launched products and late-stage R&D compounds indicated for the treatment of pain, 2006 Figure 4.13: Key players in the global pain market, 2001 and 2005 List of Tables Table 1.1: Estimated prevalence of neuropathic and nociceptive pain in the seven major pharmaceutical markets, 2005 Table 1.2: Estimated prevalence of neuropathic lower back pain in the seven major pharmaceutical markets, 2005 Table 1.3: Forecast prevalence of neuropathic lower back pain across the seven major markets, 2005–11 Table 1.4: Estimated prevalence of neuralgia/fibromyalgia pain in the seven major pharmaceutical markets, 2005 Table 1.5: Forecast prevalence of neuralgia/fibromyalgia across the seven major markets, 2005– 11 Table 1.6: Estimated prevalence of diabetic neuropathic pain (DNP) in the seven major pharmaceutical markets, 2005 Table 1.7: Forecast prevalence of diabetic neuropathic pain across the seven major markets, 2005–11 Table 1.8: Estimated prevalence of multiple sclerosis (MS) in the seven major pharmaceutical markets, 2005 Table 1.9: Forecast prevalence of pain associated with multiple sclerosis across the seven major markets, 2005–11 Table 1.10: Estimated prevalence of OA-related pain in the seven major pharmaceutical markets, 2005 Table 1.11: Estimated prevalence of RA pain in the seven major pharmaceutical markets, 2005-11 Table 1.12: Forecast prevalence of OA and RA related pain across the seven major markets, 2005-11 Table 1.13: Estimated prevalence of post-operative pain in the seven major pharmaceutical markets, 2005 Table 1.14: Forecast prevalence of post-operative pain across the seven major markets, 2005–11 Table 1.15: Estimated prevalence of cancer-related pain in the seven major pharmaceutical markets, 2005 Table 1.16: Forecast prevalence of cancer-related pain across the seven major markets, 2005–11 Table 1.17: Estimated prevalence of HIV-related pain in the seven major pharmaceutical markets, 2005 Table 1.18: Forecast prevalence of HIV-related pain across the seven major markets, 2005–11 Table 2.19: Breakdown of the global pain market by drug class, 2001-05 Table 2.20: Leading brands in the global pain market, 2004–05 Table 2.21: Leading brands in the global opioid market, 2004–06 Table 2.22: Sales forecasts for opioids in the global pain market, 2005–11 Table 2.23: Leading non-opioid products in the global pain market, 2004–05 Table 2.24: Sales forecasts for non-opioids, 2005–11 Table 2.25: Leading NSAIDs in the global pain market, 2004–05 Table 2.26: Sales forecasts for NSAIDs in the global pain market, 2005–11 Table 2.27: Leading COX-II inhibitor brands in the global pain market, 2004–05 Table 2.28: Sales forecasts for COX-II inhibitors, 2005–11 Table 2.29: Leading anti-convulsant products in the global pain market, 2004–05 Table 2.30: Sales forecasts for anti-convulsants in the global pain market, 2005–11 Table 2.31: Sales forecasts in the global pain market, 2005–11 Table 3.32: Sales forecasts for key recently launched products and R&D compounds, 2005–11 Table 4.33: Key players in the global pain market, 2005 Table 4.34: Pfizer’s marketed pain portfolio, 2005 Table 4.35: Pfizer’s pain R&D pipeline, 2006 Table 4.36: Forecast sales for Pfizer’s pain portfolio, 2005-11 Table 4.37: J&J’s marketed pain portfolio, 2005 Table 4.38: J&J’s pain R&D pipeline, 2006 Table 4.39: Forecast sales for J&J’s pain portfolio, 2005–11 Table 4.40: Novartis’ marketed pain portfolio, 2005 Table 4.41: Novartis’ pain R&D pipeline, 2006 Table 4.42 Forecast sales for Novartis’ pain portfolio, 2005–11 Table 4.43 GSK’s marketed pain portfolio, 2005 Table 4.44: GSK’s pain R&D pipeline, 2006 Table 4.45: Forecast sales for GSK’s pain portfolio, 2005–11 Table 4.46: Mundipharma’s marketed pain portfolio, 2005 Table 4.47: Forecast sales for Mundipharma’s pain portfolio, 2005–11 Table 4.48: Abbott’s marketed pain portfolio, 2005 Table 4.49: Abbott’s pain R&D pipeline, 2006 Table 4.50: Forecast sales for Abbott’s pain portfolio, 2005–11 Table 4.51: Boehringer Ingelheim’s marketed pain portfolio, 2005 Table 4.52: Forecast sales for Boehringer Ingelheim’s pain portfolio, 2005–11 Table 4.53: Sanofi-Aventis’ marketed pain portfolio, 2005 Table 4.54: Sanofi-Aventis’ pain R&D pipeline, 2006 Table 4.55: Forecast sales for Sanofi-Aventis’ pain portfolio, 2005–11

Companies Mentioned

Companies Mentioned Include: Pfizer Johnson & Johnson Novartis GlaxoSmithKline Mundipharma Int. Abbott Boehringer Ingelheim Sanofi-Aventis Drugs Mentioned Include: NW-1029 (ralfinamide) Tapentadol (CG5503/R33133) Bicifadine Transacin (NGX-4010) Neurodex (dectromorphan/quinidine) Chronogesic (sufentanil) Lacosamide M6G (morphine-6-glucuronide) Licofelone (ML3000) Lyrica (pregabalin) Prialt (ziconotide) IONSYS (fentanyl iontophoretic transdermal system) DepoDur (morphine) Prexige (lumiracoxib)